Close
Help
Need Help?





JOURNAL

Clinical Medicine Insights: Oncology

1,017,458 Journal Article Views | Journal Analytics

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib

Submit a Paper



Publication Date: 06 Dec 2012

Type: Review

Journal: Clinical Medicine Insights: Oncology

Citation: Clinical Medicine Insights: Oncology 2012:6 407-421

doi: 10.4137/CMO.S7340

Abstract

In the past decade, molecular-targeted drugs have been focused upon for the treatment of cancer. In 2002, gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor became available in Japan for the treatment of non-small cell lung cancer (NSCLC). Over 80% of selected patients, such as EGFR mutation-positive patients, respond to gefitinib treatment; however, most patients develop acquired resistance to gefitinib within a few years. Recently, many studies have been performed to determine precisely how to select patients who will respond to gefitinib, the best timing for its administration, and how to avoid the development of acquired resistance as well as adverse drug effects. This article reviews the use of gefitinib for the treatment of NSCLC from a pharmaceutical viewpoint.


Downloads

PDF  (1.31 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML

PMC HTML


Sharing




What Your Colleagues Say About Clinical Medicine Insights: Oncology
We have had a fantastic and unprecedented experience publishing our paper in Clinical Medicine Insights: Oncology.  The process of submitting and correcting the proofs were simple, quick, and smooth.  We appreciated the clarity and easiness of instructions and your fast responses to our emails. Great work.  Keep it up.
Dr Sabri Sanabani (Hemocentro de São Paulo, Brazil)
More Testimonials

Quick Links




Follow Us We make it easy to find new research papers.
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube




SUBJECT HUBS
Author Survey Results
author_survey_results
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.
See Our Results